DDInter1476 DDInter1676
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB1
Pirbuterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Pirbuterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Pirbuterol (Compound) resembles Bupranolol (Compound)
Pirbuterol (Compound) resembles Terbutaline (Compound)
Pirbuterol (Compound) treats asthma (Disease)
Pirbuterol (Compound) binds ADRB1 (Gene)
Pirbuterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Pirbuterol (Compound) causes Dry mouth (Side Effect)